Even without an oracle, it is clear that Delfi Diagnostics Inc.’s $225 million series B fundraising round positions the company well to further develop its liquid biopsy tests for early cancer detection and monitoring. Delfi’s liquid biopsy platform uses a whole genome fragmentation analysis approach for both individual cancer and multicancer detection. Read More
The U.S. CMS released the draft Medicare hospital outpatient rule for calendar year 2023, a document that is replete with information on pass-through payment data for drugs and devices. However, the agency said that the Supreme Court’s ruling regarding rates for drugs covered under the 340B drug pricing program came too late in the annual cycle to be fully accounted for in the outpatient rule for 2023, and thus any such permanent adjustments will have to wait until the outpatient rule for 2024. Read More
Qiming Venture Partners has closed funds worth a total $3.2 billion for health care-related investments, with funds spread across the five areas of biopharmaceuticals, med tech, diagnostics, health care services and IT. Read More
The value of med-tech mergers and acquisitions in the first half of 2022 are at a five-year high and about 84% ahead of last year. The volume of M&As fell significantly in the second quarter, however, with only 104 completed that were worth $46.5 billion, 27.8% less than the first quarter’s value of $64.7 billion. Regardless, M&As in the first half of 2022 are towering over each of the four prior years’ first two quarters, with a total completed of 276 worth $110.9 billion. Read More
Japan’s Ministry of Health, Labor and Welfare has cleared Japan Tissue Engineering Co. Ltd.’s (J-Tec) autologous cultured cartilage, called Jacc, after a seven-year re-examination period. Headquartered in Gamagori, in Japan’s Aichi prefecture, J-Tec was the first company in Japan to receive conditional clearance of regenerative medicine therapies under the new regenerative medicine pathway. Read More
New hires and promotions in the med-tech industry, including: Atonarp, Avantor, Brainomix, Huma.AI, Integra Lifesciences, Invitae, Koneksa, Matterworks, Mimedex. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alpenglow, Anpac Bio, Coreplus, Caption Health, CN Innovations, Durastat, Paragonix, Pillar Biosciences, Prevencio, Rite Aid, Quest Diagnostics, Synchron. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Neuronetics. Read More
